Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

23.02.2026

3 Antiviral Res
3 Arch Virol
1 Epidemiol Infect
1 J Gen Virol
1 J Infect
6 J Infect Dis
5 J Virol
1 JAMA
2 MMWR Morb Mortal Wkly Rep
1 N Engl J Med
13 PLoS One
1 Proc Natl Acad Sci U S A
22 Vaccine


    Antiviral Res

  1. WRONSKI S, Obernolte H, Schaudien D, Braun A, et al
    Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice.
    Antiviral Res. 2026;247:106362.
    >> Share

  2. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
    >> Share

  3. RODRIGUEZ L, Hu Y, Li J, Han D, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339.
    >> Share


    Arch Virol

  4. LIM KS, Selvan ME, Ea CK, Teo CH, et al
    CircRNA expression profiling in H1N1-infected primary human tracheobronchial epithelial cells identifies candidate immune-related circRNAs validated in A549 cells.
    Arch Virol. 2026;171:85.
    >> Share

  5. JAMAL Z, Haider SA, Humayun F, Ali Q, et al
    Genomic surveillance of Influenza, SARS-CoV-2, and RSV in patients from Islamabad and Rawalpindi, Pakistan: a 2023-24 perspective.
    Arch Virol. 2026;171:78.
    >> Share

  6. SHILOVA NV, Yermolaeva DR, Nokel AY, Chinarev AA, et al
    Antibody-free detection of influenza viruses on a microarray to study their receptor specificity.
    Arch Virol. 2026;171:75.
    >> Share


    Epidemiol Infect

  7. MARQUEZ J, Garcia-Garcia D, Vigo MI, Bordehore C, et al
    Retrospective estimate of COVID-19 infections in nine Colombian cities in 2020.
    Epidemiol Infect. 2026;154:e22.
    >> Share


    J Gen Virol

  8. PAN X, Shi X, Zhao L, Yan D, et al
    Amino acid mutations K54E and S154P in the neuraminidase attenuate H3N2 canine influenza virus in mice.
    J Gen Virol. 2026;107.
    >> Share


    J Infect

  9. LIU K, Wang X, Huang J, Liu P, et al
    Zoonotic Threat of Novel H6N2 Avian Influenza Virus with Internal Genes Exclusively Derived from H9N2, China, 2025.
    J Infect. 2026 Feb 18:106705. doi: 10.1016/j.jinf.2026.106705.
    >> Share


    J Infect Dis

  10. CHAPPELL KJ, Mordant FL, Amarilla AA, Modhiran N, et al
    Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial.
    J Infect Dis. 2025 Nov 25:jiaf568. doi: 10.1093.
    >> Share

  11. IGLESIAS-CABALLERO M, Mas V, Campoy A, Calvo C, et al
    Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.
    J Infect Dis. 2026;233:e409-e418.
    >> Share

  12. HOFSINK Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, et al
    COVID-19 Vaccine Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study.
    J Infect Dis. 2025 Oct 14:jiaf523. doi: 10.1093.
    >> Share

  13. EDWARDS DL, Feldstein LR, Dalton AF, Ford ND, et al
    Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022.
    J Infect Dis. 2026;233:e352-e362.
    >> Share

  14. LI B, Ke Y, Chen X, Martinez L, et al
    Robust COVID-19 Mortality Risk Assessment: Validation of a Two-Step Algorithm From the National COVID Cohort Collaborative.
    J Infect Dis. 2026;233:351-362.
    >> Share

  15. OKABE H, Hashimoto K, Norito S, Ono T, et al
    Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains.
    J Infect Dis. 2026;233:334-341.
    >> Share


    J Virol

  16. HAZELL NC, Reyna RA, Adam A, Bonam SR, et al
    mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models.
    J Virol. 2026 Jan 7:e0189725. doi: 10.1128/jvi.01897.
    >> Share

  17. MASTERS PS
    Coronavirus genome packaging and nucleocapsid assembly.
    J Virol. 2026 Jan 8:e0133025. doi: 10.1128/jvi.01330.
    >> Share

  18. ALVARADO RE, Lokugamage KG, Garvanska D, Estes LK, et al
    Key residues in SARS-CoV-2 NSP3 hypervariable region are necessary to modulate early stress granule activity.
    J Virol. 2026 Jan 14:e0200625. doi: 10.1128/jvi.02006.
    >> Share

  19. TIEN C-F, Lin E-J, Tsai W-H, Tsai W-T, et al
    SARS-CoV-2 spike protein expression drives post-acute coagulopathy.
    J Virol. 2026 Jan 21:e0125525. doi: 10.1128/jvi.01255.
    >> Share

  20. NAKANO T, Esaki M, Inoue A, Koike F, et al
    Impact of an amino acid deletion detected in the hemagglutinin (HA) antigenic site of swine influenza A virus field strains on HA antigenicity.
    J Virol. 2026 Feb 19:e0182025. doi: 10.1128/jvi.01820.
    >> Share


    JAMA

  21. DILEK S, Rosen J, Levashkevich A, Sharfstein JM, et al
    The US Food and Drug Administration's Regulation of Mifepristone.
    JAMA. 2026 Jan 12. doi: 10.1001/jama.2025.23091.
    >> Share


    MMWR Morb Mortal Wkly Rep

  22. SILK BJ, Prill MM, Winn AK, Patton ME, et al
    Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:77-84.
    >> Share

  23. RAYKIN J, Rochin I, Wiegand R, Soto V, et al
    COVID-19 Antiviral Prescription Receipt Among Outpatients Aged >/=65 Years - United States, June 1, 2023-September 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:69-76.
    >> Share


    N Engl J Med

  24. RASMUSSEN SA, Jernigan DB
    Antigenic Drift and Antivaccine Shift in the 2025-2026 Influenza Season.
    N Engl J Med. 2026;394:732-735.
    >> Share


    PLoS One

  25. ROONEY G, Loibl C
    Scarcity mindset's positive association with using alternative financial services.
    PLoS One. 2026;21:e0339127.
    >> Share

  26. KAKKAR M, Sharma D, Pal M, Mohapatra A, et al
    An analysis of WHO FluNet and FluID influenza surveillance data for South East Asia Region, 2015-2023.
    PLoS One. 2026;21:e0341567.
    >> Share

  27. CHAKRABORTY A, Diwan A, Chiniga V, Arora V, et al
    Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.
    PLoS One. 2026;21:e0324811.
    >> Share

  28. THAKUR A, Meza-Torres B, Fan X, Byford R, et al
    Prediction of COVID-19 hospitalisation, ICU admission or death following ChAdOx1 vaccination using artificial intelligence: A clinical predictive model from the English RAVEN study.
    PLoS One. 2026;21:e0336449.
    >> Share

  29. LI J, Xie Z, Chen Y, Jin G, et al
    Trends and associations of pulmonary nodule detection rates in China, 2019-2023: A multicenter cross-sectional study based on Real-World Data.
    PLoS One. 2026;21:e0343207.
    >> Share

  30. ROBERTSON LS
    Prayer, politics, and policy related to age-adjusted cancer, heart disease, infant mortality, and COVID-19 death Rates, U.S. states 2018-2021.
    PLoS One. 2026;21:e0343211.
    >> Share

  31. WILLANE CT, Sylla PMDD, Thiam M, Ndiaye BM, et al
    Optimizing nutritionally adequate food basket using linear programming in Niayes Households, Senegal.
    PLoS One. 2026;21:e0343156.
    >> Share

  32. KHEZRIMOTLAGH D, Imanpour S, Akbas E
    Reassessing the emergency department burden of influenza: A comprehensive real-world analysis using administrative data.
    PLoS One. 2026;21:e0340699.
    >> Share

  33. CARTWRIGHT T, Metcalf L, Wadhen V
    'It is a lifeline': International cross-sectional survey of benefits, barriers and acceptability of online yoga during the COVID-19 pandemic.
    PLoS One. 2026;21:e0341852.
    >> Share

  34. DIDRIKSSON I, Toniste D, Hultgren M, Spangfors M, et al
    Three-year functional, physical, and mental health outcomes after critical COVID-19: A prospective multicentre cohort study.
    PLoS One. 2026;21:e0341319.
    >> Share

  35. LEONTI M, Mollica C, Spadaccini S, Casu L, et al
    Treatments for COVID-19 and acute respiratory infections are associated with gender and comorbidities in an Italian online survey.
    PLoS One. 2026;21:e0342466.
    >> Share

  36. MCMASTER JMV, Gellersen HM, Korkki SM, Simons JS, et al
    The impact of lifestyle restrictions on memory in older adults.
    PLoS One. 2026;21:e0342458.
    >> Share

  37. MARTINEZ-BORBA V, Rodriguez-Marquez AE, Garces-Arilla S, Peris-Baquero O, et al
    Effectiveness and acceptability of the unified protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19: Study protocol for a randomized controlled trial.
    PLoS One. 2026;21:e0342908.
    >> Share


    Proc Natl Acad Sci U S A

  38. LIU C, Zheng J, Wang Y, Beck F, et al
    Cryo-EM structure of locked spike glycoprotein from bat SARS-like coronavirus WIV1, molecular dynamics and biophysics across host range.
    Proc Natl Acad Sci U S A. 2026;123:e2516874123.
    >> Share


    Vaccine

  39. SOBLE A, Koh M, Taaffe J, Procter SR, et al
    Evaluating the broader impact of improved influenza vaccines: A full value of vaccine assessment approach.
    Vaccine. 2026;60 Suppl 2:128166.
    >> Share

  40. CONTARINO F, Fiorilla C, Bella F, Leonforte F, et al
    Missed opportunities and co-administration patterns for influenza vaccination in older adults in Italy: a retrospective cohort study.
    Vaccine. 2026;77:128366.
    >> Share

  41. GREEN MA, Jeffery C, Cheyne C, Bonnett L, et al
    Learning from the outliers: A longitudinal ecological study of social and spatial inequalities in older adult influenza vaccination and hospitalisation (Cheshire and Merseyside, UK, 2018-19 to 2023-24).
    Vaccine. 2026;77:128356.
    >> Share

  42. ANDERSON SA, Smith ER, Wan Z, Amend KL, et al
    Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.
    Vaccine. 2026;75:128225.
    >> Share

  43. SHARMA AJ, Smoots AN, Madni SA, Zauche LH, et al
    COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.
    Vaccine. 2026;75:128268.
    >> Share

  44. TONDEL C, Jenum S, Tonby K, Christensen EE, et al
    SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial.
    Vaccine. 2026;75:128290.
    >> Share

  45. KENEALY T, Aguirre-Duarte N, Roxburgh RH, Royle G, et al
    Accuracy of ICD and SNOMED search strategies for adverse events following COVID-19 vaccination: Analysis of hospital administrative data.
    Vaccine. 2026;75:128275.
    >> Share

  46. PARK IY, Cantu-Aldana A, Grafft N, Lo BK, et al
    Fathers' reports of within-household vaccine decision making and young children's COVID-19 vaccination status.
    Vaccine. 2026;75:128282.
    >> Share

  47. THAKKAR K, Kefalogianni R, Zhang J, Yung CF, et al
    Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore.
    Vaccine. 2026;75:128285.
    >> Share

  48. LOTSPEICH-COLE L, Jha MK, Parvathaneni S, Lee RC, et al
    Neonatal mice immune response to COVID-19 mRNA vaccine.
    Vaccine. 2026;75:128271.
    >> Share

  49. HAHM HC, Tang M, Lupaczyk L, Lee J, et al
    Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis.
    Vaccine. 2026;75:128283.
    >> Share

  50. BARBER C, Barber M, Lee JSW, Ting J, et al
    Vaccination policies, practices, and procedures in level-III neonatal intensive care units across Canada: An environmental scan.
    Vaccine. 2026;75:128261.
    >> Share

  51. VATTOTH AL, Hayney MS, Forati AM, Warren B, et al
    Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.
    Vaccine. 2026;75:128208.
    >> Share

  52. YESENIA RODRIGUEZ-TANTA L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, et al
    Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
    Vaccine. 2026;75:128227.
    >> Share

  53. YIGIT I, Stoner MCD, Muessig KE, Hightow-Weidman LB, et al
    Pathways to COVID-19 vaccine initiation: The roles of medical mistrust, conspiracy beliefs, hesitancy, and confidence among black young adults.
    Vaccine. 2026;75:128253.
    >> Share

  54. HANDY AB, Ren B, Seidman LC, Granger SW, et al
    Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination in adolescents.
    Vaccine. 2026;75:128226.
    >> Share

  55. FAIJUE DD, Bouaddi O, Mackey K, Deal A, et al
    Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.
    Vaccine. 2026;75:128249.
    >> Share

  56. MALTEZOU HC, Giannouchos TV, Gamaletsou MN, Koukou DM, et al
    Absenteeism related to respiratory infections among healthcare personnel in hospitals in Greece from 2020-2021 to 2024-2025.
    Vaccine. 2026;75:128264.
    >> Share

  57. ADAM A, Lee C, Jones MC, Harrington BR, et al
    VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.
    Vaccine. 2026;75:128255.
    >> Share

  58. OKOLI GN, Kwan MYW, Chan ELY, Murphy C, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study.
    Vaccine. 2026;75:128262.
    >> Share

  59. MANSFIELD ME, Okui L, Simon S, Hosangadi D, et al
    Understanding COVID-19 vaccination choices and development of a toolkit and training for Botswana, 2022-2023.
    Vaccine. 2026;75:128274.
    >> Share

  60. PAXITZIS AN, Oyebanji OA, Olagunju OJ, Keresztesy D, et al
    Antibody responses to SARS-CoV-2 vaccine in nursing home residents support a Bi-annual update schedule.
    Vaccine. 2026;75:128240.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016